Venclexta (venetoclax) 100 mg 112 tab. Ireland

 Indication

  Venclixto® in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic (lymphoid) leukemia (CLL).

  Venclixto® in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior line of therapy.

  The drug Venclixto® is indicated as monotherapy in CLL:

  in patients with deletion of chromosome 17p or mutation of the TP53 gene, who are not suitable for treatment with a B-cell receptor inhibitor or for whom such treatment was ineffective;

  in patients without 17p deletion or TP53 gene mutation, if chemotherapy and B-cell receptor inhibitor treatment have failed.

  The drug Venclixto® in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who cannot be prescribed intensive chemotherapy.